Antioxidant Therapy Reduces Oxidative Stress, Restores Na,K-ATPase Function and Induces Neuroprotection in Rodent Models of Seizure and Epilepsy: A Systematic Review and Meta-Analysis

Abstract

Epilepsy is a neurological disorder characterized by epileptic seizures resulting from neuronal hyperexcitability, which may be related to failures in Na,K-ATPase activity and oxidative stress participation. We conducted this study to investigate the impact of antioxidant therapy on oxidative stress, Na,K-ATPase activity, seizure factors, and mortality in rodent seizure/epilepsy models induced by pentylenetetrazol (PTZ), pilocarpine (PILO), and kainic acid (KA). After screening 561 records in the MEDLINE, EMBASE, Web of Science, Science Direct, and Scopus databases, 22 were included in the systematic review following the PRISMA guidelines. The meta-analysis included 14 studies and showed that in epileptic animals there was an increase in the oxidizing agents nitric oxide (NO) and malondialdehyde (MDA), with a reduction in endogenous antioxidants reduced glutathione (GSH) and superoxide dismutase (SO). The Na,K-ATPase activity was reduced in all areas evaluated. Antioxidant therapy reversed all of these parameters altered by seizure or epilepsy induction. In addition, there was a percentage decrease in the number of seizures and mortality, and a meta-analysis showed a longer seizure latency in animals using antioxidant therapy. Thus, this study suggests that the use of antioxidants promotes neuroprotective effects and mitigates the effects of epilepsy. The protocol was registered in the Prospective Register of Systematic Reviews (PROSPERO) CRD42022356960.

1. Introduction

Epilepsy is a chronic neurological disorder that affects more than 70 million people worldwide, with a generally bimodal incidence that mainly affects children and the elderly [1]. It is characterized by a persistent propensity to develop epileptic seizures due to abnormal excessive or synchronous neuronal activity in the brain [2]. The molecular mechanisms underlying the development of epilepsy are related to neural injury resulting from several factors, including oxidative stress (OS) in neural tissues [3,4,5,6].

Oxidative stress occurs when the antioxidant defense system, consisting of endogenous antioxidants, such as catalase (CAT), glutathione peroxidase (GPx), glutathione reductase (GR), superoxide dismutase (SOD), and reduced glutathione (GSH), and a variety of exogenous antioxidants obtained from the diet, cannot eliminate excess reactive species (RS) which are the result of cellular metabolism and/or external factors [7,8,9,10,11].

The combination of excessive reactive oxygen species (ROS) production with nitric oxide (NO) to form peroxynitrite, a reactive nitrogen species, leads to lipid peroxidation and direct protein damage, which alters membrane and cell functions [12,13,14]. This fact makes the brain highly susceptible to oxidative stress because of its high metabolism and high concentrations of unsaturated fatty acids [15].

As a consequence of oxidative metabolism and lipid peroxidation, damage occurs to the constituents of neuronal membranes, including Na,K-ATPase (NKA) [16,17]. This enzyme maintains the electrical activity of excitable cells and is essential for the maintenance of cellular homeostasis, as it is responsible for the ionic composition within the cells and osmotic balance [18,19]. Consequently, failures in the NKA activity can interfere with cell excitability and facilitate the onset or propagation of a seizure [20,21].

In order to improve antioxidant defense, antioxidant therapy can be performed through the ingestion of substances with antioxidant activity, either through an adequate diet or through supplementation [22,23,24]. Several studies report benefits with the use of antioxidant therapy in animal models of neurological disorders [25,26,27,28] and in human studies [29,30,31]. Preclinical studies have indicated that antioxidant therapy reduces oxidative damage and epileptogenic potential [32,33,34]. However, clinical studies are controversial. Studies have shown a reduction in seizures [35] and oxidative stress [36,37]. Other studies have indicated no significant changes in seizure frequency [38].

Animal models have been widely used for the study of epilepsy, and the most commonly used proconvulsants to induce this model are pilocarpine (PILO), kainic acid (KA), and pentylenetetrazole (PTZ). PILO and KA induce a model of chronic temporal lobe epilepsy, which affects some neural substrates such as the hippocampus and cortex [39,40,41,42,43]. Pilocarpine is a cholinergic agonist and kainic acid is an l-glutamate analogue and an agonist of AMPA and kainic acid receptors; both induce seizures that progress to epilepsy [40,41,42]. PTZ, used as an acute seizure model, induces generalized seizures by decreasing GABAergic function through antagonism of GABAa receptors [44]. All these models allow the study of postictal abnormalities.

Considering the importance of epilepsy and the therapeutic potential of antioxidants, we conducted a systematic review and meta-analysis of preclinical studies that investigated the action of different antioxidants in animal models of seizures or epilepsy. The aim of this study was to investigate the effects of different antioxidant therapies on oxidative stress and Na,K-ATPase activity in neural tissue in a rodent model of seizures or epilepsy and to verify the impact of this use on seizure parameters and mortality. In this way, advances can be made in the knowledge related to biochemical factors, safety, and neuroprotection on the use of these antioxidants in preclinical studies of seizures and epilepsy, which will enable future clinical studies.

2. Materials and Methods

This review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [45]. The PICO and PECO were used because this study was divided into Intervention and Exposure groups. Thus, we have Population (P)—rats and mice; Intervention (I)—antioxidant therapy or Exposure (E)—epilepsy; Comparison (C)—control or sham animals; and Outcomes (O)—NKA activity, oxidative stress, and behavioral changes. The protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) CRD42022356960.

2.1. Research Strategy and Selection of Studies

To verify the effect of antioxidant therapy on NKA activity in experimental models of epilepsy, a systematic search was performed using MEDLINE (PubMed), EMBASE, Web of Science, Science Direct, and Scopus, regardless of publication date.

The following descriptors that could be in the titles, abstracts, and/or keywords were used: for epilepsy (epileps*, “epilepsy seizure”, convulsion, seizure), for Na,K-ATPase (“sodium, potassium exchanging ATPase”, “sodium potassium ATPase”, “sodium potassium adenosinetriphosphatase”, “ATPase sodium potassium”, “Na⁺K⁺ transporting ATPase”, “Na⁺K⁺ exchanging ATPase”, “Na⁺K⁺-ATPase”, “sodium pump”, “sodium potassium pump”, “adenosine triphosphatase”, “Na/K-ATPase”), and for oxidative stress combined with antioxidants (“oxidative stresses”, “oxidative stress”, “nitro oxidative stress”, “nitro-oxidative stress”, “oxidative injury”, “oxidative damage”, antioxidants, anti-oxidant, “antioxidant activity”). Among the descriptions the term OR was used and among the three groups of descriptors combined with each other, the term AND was used. The beginning and end of the study searches were 1 and 3 March 2022, respectively, with updates between 5 and 7 December 2022.

The eligibility criteria for the inclusion of studies were as follows: (1) The experimental models of epilepsy must be rats or mice. (2) Epilepsy can be chemically induced only by PILO, PTZ, or KA. (3) The study must analyze the activity of NKA in brain tissues and part of the epileptic animals should receive one antioxidant regardless of dosage and route of administration. (4) Experimental studies should include control animals or sham animals for comparison purposes. (5) Articles should be published in English, Portuguese, or Spanish. The following were excluded: (1) studies that used rats or mice with other associated pathologies and (2) literature review articles, abstracts, conference presentations, and book chapters.

After identifying studies in the databases, the articles were imported into the Rayyan software [46]. Duplicate studies were removed, and screening was performed by two blinded reviewers who independently evaluated the titles and abstracts of the studies. If there was disagreement, a third reviewer participated. After this procedure, the eligibility criteria were applied to the full articles, judging by inclusion or exclusion from this systematic review and meta-analysis. All studies that met the eligibility criteria but did not provide sufficient information, such as the sample size, were excluded from the meta-analysis; however, they were included in the systematic review.

2.2. Data Extraction and Assessment of Risk of Bias

One author (AM) extracted all data, which were verified by a second author (ID). Any disagreements were resolved by a third author (LC). Data extracted from primary studies were summarized in this systematic review and evaluated in the meta-analysis when at least 3 analyses were available: NKA activity, enzymatic antioxidant activity (superoxide dismutase—SOD, catalase—CAT, glutathione peroxidase—GPx, glutathione reductase—GR, glutathione S-transferase—GST), and GSH and oxidizing agents (malondialdehyde—MDA, protein carbonyl—PCA, nitric oxide—NO, RS). These data were considered when extracted from brain regions, and biochemical data extracted from the blood were not considered. Seizure latency, the number of seizures, and mortality were also recorded. WebPlotDigitizer software, version 4.5 [47], was used to collect the data available only in the graphs.

In addition, the following information was collected: (1) name of the first author and year of publication; (2) animal model, sex, and weight; (3) epilepsy-inducing drug, as well as the dosage and route of administration; (4) sample size of each experimental group; (5) type of antioxidant, as well as its dosage, form of administration, and duration of use; and (6) name of all outcomes.

Risk of bias assessment was performed using the Systematic Review Center for Laboratory Animal Experimentation (SYRCLE) tool by two independent reviewers. Possible sources of bias were verified in all studies included in this systematic review and divided into six large groups: selection, performance, detection, attrition, information, and other sources of bias. Details of the issues related to the inquiries are available in Supplementary Data N° 1.

2.3. Data Analysis

All data were analyzed using Revision Manager software [48]. The statistical method used was inverse variance, with random effects as the model of analysis, and the difference in the standardized mean as a measure of effect. For all analyses, statistical significance was set at p < 0.05, which was considered statistically significant [49]. The I² statistic was used to assess heterogeneity, considering heterogeneity ≤40% as unimportant, 30–60% as moderate, and ≥75% as considerable [50]. Studies that presented data expressed as mean ± standard error (SEM) were converted into mean ± standard deviation (SD) using the following formula: SD = √n × standard error.

3. Results

3.1. Search Results

A total of 561 studies were identified from the five databases. After the removal of duplicate articles and screening of titles and abstracts, only the full text of 71 studies were analyzed. After this full-text analysis, 22 studies were included in the systematic review, of which 14 were included in the meta-analysis (Figure 1). The number of studies entered for each outcome and the location of the brain area analyzed are shown in Supplementary Data N° 2.

3.2. Assessment of the Risk of Bias

The results of the risk of bias assessment are presented in Table 1. The risks of selection bias, performance, detection, attrition, information, and others were evaluated and divided into ten questions. Of the 22 primary studies analyzed, 50% had a low risk of selection bias, whereas 16.7% had a high risk of bias. On the other hand, 52.3% of the studies were inaccurate regarding the risk of performance bias, while 47.7% were considered low risk. Detection and attrition biases each had a high risk of bias of 50%. Regarding information bias and other biases, there was a predominance of a low risk of bias (100% and 81.8%, respectively).

3.3. Animal and Antioxidant Characteristics of the Included Studies

The primary studies are summarized in Table 2 and were published between 2004 and 2022. Most studies (54.5%) used Wistar rats, followed by Swiss mice (36.4%), and Sprague Dawley rats (9.1%). All males had weights ranging from 150 to 300 g, except for one study that used animals of 21 days weighing between 40 and 50 g. In addition, the weights of the mice ranged from 18 g to 35 g. The sample size of each group ranged from five to fourteen animals for biochemical analysis.

Among these studies, only one used 10 mg/kg KA as an epilepsy-inducing drug. PILO was used in eight studies at dosages ranging from 300 to 400 mg/kg. PTZ was used in 13 articles, with dosages from 1.8 µmol to 90 mg/Kg. The main route of administration was the intraperitoneal route, which corresponded to 90.9%, in addition to the intrastriatal route in 9.1% of the studies.

Twenty different antioxidants were used in these studies, and only lipoic acid, creatine, and GM1 are considered endogenous antioxidants, while the others are classified as exogenous antioxidants. The dosages used in the primary studies varied between 10 and 300 mg/kg; 63.6% used the oral route to administer antioxidants, while the other studies used the intraperitoneal route. Furthermore, the majority of the animals were administered antioxidants between 30 and 60 min before the induction of epilepsy (Table 2).

3.4. Biochemical Parameters

Table 2 presents the summarized data of the biochemical parameters, showing the results obtained in each study included in the Systematic Review and separating the data obtained in the epilepsy and epilepsy + antioxidant groups.

3.4.1. Oxidizing Agent

This systematic review collected data from studies evaluating oxidizing agents in the whole brain, hippocampus, cortex, and striatum. In the whole brains of epileptic animals, an increase in RS, NO, and MDA was observed in all analyses. With the use of exogenous antioxidants, there was a reduction in most of the RS (88.9%), NO (75%), and MDA (68.4%) levels. Studies in the hippocampus of epileptic animals showed that, in seven analyses of MDA, six showed an increase. This increase also occurred in PCA, RS, and NO analyses. The use of exogenous antioxidants indicates that in most analyses of PCA, NO, and MDA, there is a reduction in their levels in the hippocampus. This was also observed in the three analyses of RS. Furthermore, in the cortex of epileptic animals, there was an 80% increase in PCA analyses, in all MDA analyses, and in one study with RS. Regarding antioxidant treatment, there was a reduction in MDA and PCA levels by 100% and 66.7%, respectively. Regarding the RS data, in three analyses only one showed a reduction. In the striatum region, which showed an increase in MDA and PCA in epileptic animals, after treatment with exogenous antioxidants it only reduced in one PCA and in MDA analysis (Table 2).

The meta-analysis confirmed that there was an increase in NO levels in the whole brain (SMD = 3.96 [95% CI: 1.22 to 6.70] p = 0.005, I² = 76%) and the hippocampus (SMD = 2.67 [95% CI: 1.65 to 3.70] p < 0.001, I² = 25 %) of epileptic animals (Figure 2A). Furthermore, the use of antioxidants (Figure 2B), there was a reduction in NO levels in the whole brain (SMD = −2.12 [95% CI: −3.24 to −1.01], p = 0.0002, I² = 48%) and hippocampus (SMD = −1.05 [95% CI: −1.61, −0.49], p = 0.0002, I² = 0%).

Regarding MDA levels, the meta-analysis indicated an increase in epilepsy in the three areas evaluated (Figure 3A). In the whole brain, the data were (SMD = 7.85 [95% CI: 2.75 to 12.94] p = 0.003, I² = 83%). In the hippocampus and cortex, the results obtained were (SMD = 2.38 [95% CI: 1.02 to 3.75] p < 0.001, I² = 81%) and (SMD = 2.32 [95% CI: 0.86 to 3.78] p = 0.002, I² = 41%), respectively. With the use of antioxidants, there was a reduction in MDA levels in the three areas evaluated in epileptic animals treated with exogenous antioxidants (Figure 3B). For the whole brain, the following results were observed (SMD = −3.18 [95% CI: −4.93 to −1.43] p < 0.001, I² = 68%). In the hippocampus and cortex, they were (SMD = −1.47 [95% CI: −2.03 to −0.90] p < 0.001, I² = 39%) and (SMD = −2.82 [95% CI: −4.78 to −0.85] p = 0.005, I² = 76%), respectively.

3.4.2. Antioxidant System

The survey of primary studies conducted through the systematic review indicated that the antioxidant system was evaluated in five areas: the whole brain, hippocampus, cortex, striatum, and cerebellum (Table 2).

In the whole brain of untreated epileptic animals, there was a reduction in GSH levels and in all analyses of SOD, GR, and GPx activities, with an increase in GST and CAT activities in the two analyses. With antioxidant therapy, there was an increase in GSH levels and SOD and GR activity by 83.3%, 81.3%, and 100% of the analyses, respectively. However, there were no differences in the activities of GST (88.9%), CAT (70%), and GPx (100%). In the hippocampi of epileptic animals, there were reductions in GSH levels and GR activity in the analyses performed, whereas CAT activity was reduced in 66.6% of the analyses. Of the five SOD activity analyses, only two showed a reduction in the number of animals with epilepsy. GPx activity was assessed in three studies, with a reduction in only one of them. The use of antioxidants increased GSH levels and SOD and GPx activities by 57.1%, 60%, and 50%, respectively. It also increased in only one of two analyses. The use of antioxidants increased CAT activity in the three analyses but had no effect in the other three evaluations. In the cortex, only one study has evaluated SOD, GPx, and GSH levels in animals with epilepsy. There was an increase in SOD activity and a reduction in GSH levels, but no statistical difference in GPx activity. Regarding the use of exogenous antioxidants, it was observed that there was an increase in GSH levels with a reduction in SOD activity, whereas there was no effect on GPx activity (Table 2).

From the studies from which the meta-analysis could be performed, it was observed that in the whole brain (SMD = −9.34 [95% CI: −16.32 to −2.36], p = 0.009, I² = 85%) and hippocampus (SMD = −5.01 [95% CI: −7.72 to −2.30] p = 0.0003, I² = 82%) there was a reduction in GSH levels in epileptic animals (Figure 4A). There were increases in GSH levels in the brains of epileptic animals after antioxidant therapy (Figure 4B) (SMD = 4.99 [95% CI: 2.23 to 7.75] p = 0.0004, I² = 77%) and the hippocampi (SMD = 2.10 [95% CI: 0.80 to 3.41] p = 0.002, I² = 71%).

The SOD activity was reduced in the whole brains of epileptic animals (Figure 5A) (SMD= −5.50 [95% CI: −7.59 to −3.41] p < 0.001, I² = 51%), while the use of exogenous antioxidants increased their activity (SMD = 3.54 [95% CI: 2.44 to 4.64] p < 0.001, I² = 28%). In the hippocampus, no difference in SOD activity was observed in the two comparisons: epileptic and control (SMD = −0.87 [95% CI: −3.21 to 1.47], p = 0.47, I² = 90%) and epileptic without and with the use of antioxidants (SMD = 0.40 [95% CI: −1.54 to 2.35], p = 0.69, I² = 88%).

CAT was evaluated only in the hippocampus (Figure 6), and there were no differences between epileptic and control animals in the five analyses (SMD = −1.32 [95% CI: −3.07 to 0.43], p = 0.14, I² = 89%). There were also no differences between epileptic animals using exogenous antioxidants in the nine analyses (SMD = 0.10 [95% CI: −0.97 to 1.17] p = 0.85, I² = 81%).

3.4.3. NKA Activity

NKA activity was assessed in four different regions of the central nervous system of epileptic animals in addition to the whole brain. There was a reduction in 100 % of NKA activity analyses in the whole brain and striatum. In the hippocampus and cortex, there were reductions of 90.9% and 75% in the analyses, respectively. In intervention studies using antioxidants, NKA activity was restored in most of the analyses. In the cortex, striatum, hippocampus, and whole brain, there were increases in NKA activity in 66.7%, 60%, 75%, and 86.4% of the analyses, respectively. In the cerebellar region, only one study on NKA activity was performed, with no difference in either disease exposure or intervention analysis.

Meta-analysis (Figure 7A) indicated the effect of epilepsy on NKA activity in these three areas. There was a reduction in NKA activity in the whole brains (SMD = −7.35 [95% CI: −10.62 to −4.08] p < 0.0001, I² = 67%), hippocampi (SMD = −3.60 [95% CI: −4.82 to −2.39] p < 0.0001, I² = 75%), and cortexes (SMD = −2.17 [95% CI: −3.80 to −0.54] p = 0.009, I² = 75%) of epileptic animals when compared to control animals. Figure 7B shows the effects of antioxidant therapy in epileptic animals. There was an increase in NKA activity in all three areas analyzed: the whole brain (SMD = 3.55 [95% CI: 1.70 to 5.40] p = 0.0002, I² = 76%), in the hippocampus (SMD = 2.58 [95% CI: 1.66 to 3.49] p < 0.00001, I² = 76%), and in the cortex (SMD = 3.93 [95% CI: 1.29 to 6.57] p = 0.004, I² = 88%).

3.5. Seizure-Related Outcomes and Mortality

Seizure-related outcomes included the seizure frequency and latency. The use of antioxidants decreases seizure frequency and mortality in animals with epilepsy. Of the 117 animals that were not treated with the antioxidants (Figure 8A), 112 animals experienced seizures (95.7%). Of the 191 animals that received antioxidant treatment, 68 experienced seizures (35.6%). Among 117 epileptic animals evaluated, 55.6% died of epilepsy. This percentage decreased to 15.7% when epileptic animals received exogenous antioxidants.

Regarding latency (Figure 8B), a meta-analysis was performed on 216 epileptic animals and 130 animals that received exogenous antioxidants. The results (SMD = 5.90 [95% CI: 4.05 to 7.75] p < 0.00001, I² = 93%) indicated that the use of exogenous antioxidants increased the seizure latency of epileptic animals. Except for the studies by [62,63], all other studies evaluated the latency period up to 60 min after the induction of epilepsy with PTZ or PILO. Notably, induction occurred between 30 min and 60 min after the use of antioxidants.

3.6. Summary of Meta-Analyses

Table 3 summarizes the results of the meta-analysis, indicating whether there was an increase or decrease in the levels or activities of the outcomes. Non-significant data are indicated as n.s.

4. Discussion

Epilepsy is a devastating neurological disorder. In this meta-analysis, we demonstrated the neuroprotective effects of exogenous antioxidants in an experimental epilepsy model.

Oxidant agents arise from excitotoxicity resulting from hyperstimulation of the glutamatergic system, observed in epilepsy. Due to the exacerbated increase of glutamate in the synaptic cleft, NMDA (N-methyl-D-aspartate) receptors are excessively stimulated, which causes an accentuated influx of calcium ions. One consequence of this influx of calcium ions into the intracellular environment is the production of NO by neuronal nitric oxide synthase (nNOS), which is linked to the NMDA receptor by the PSD95 protein [72,73]. They can react with superoxides to form peroxynitrite, which causes cell damage [13].

In the present study, there was an increase in NO levels in the brains and hippocampi of epileptic animals compared to control animals, with a possible protective action resulting from the reduction in NO after the use of exogenous antioxidants. Another relevant point of exacerbated NMDA receptor activation is the production of RS, which can occur through NADPH oxidase [73] and metabolic stress in mitochondria [74,75]. NO can react with superoxides from NADPH oxidase and mitochondria to produce peroxynitrite, which can be decomposed to form hydroxyl radicals that are highly toxic to cells [76]. The formation of different RS plays an essential role in lipid peroxidation, which causes rupture of cell membranes, altering permeability, and leading to cell death. MDA is a product of lipid peroxidation [59,64] and has been evaluated using meta-analysis. It was observed that the experimental rodent models of seizure epilepsy used, PILO, KA, and PTZ, showed increased levels of MDA in the brain, hippocampus, and cortex, and antioxidant therapy was able to reverse the increase in MDA levels in epileptic animals in all evaluated areas.

We also found that PCA and RS levels increased in epileptic animals, except in the study by Bortolatto et al. (2011) [58] in cortical areas. According to the authors, this is due to the higher specificity of KA for the hippocampal region, which also influences the data with the use of exogenous antioxidants. Additionally, Wilhelm et al. (2010) [55] used six different dosages of the antioxidant BPD and found no difference in RS levels at the lowest dosage of 1 mg/kg.

In addition to the oxidant factors, it was possible to evaluate the endogenous antioxidant system by meta-analysis by evaluating the levels of GSH and the enzymatic activities of SOD and CAT. There are controversies regarding GSH studies. Some studies have pointed out that the use of antioxidants at low concentrations does not affect GSH levels [62,64,66], whereas Ezz et al. (2011) [57] suggested that they did not increase GSH levels after using the antioxidant NSO due to one of its components, thymoquinone, being reported as being able to cause GSH depletion. Human studies have shown a reduction in total GSH levels in the blood of children with focal epilepsy compared with children without a diagnosis of epilepsy [77]. However, no difference was observed in another prospective study involving 100 patients [78].

This meta-analysis showed that GSH levels were reduced in the brain and hippocampus of epileptic animals and reversed after the use of exogenous antioxidants. These results agreed with those reported by Hussein et al. (2014) [79], who found a reduction in GSH levels in the brains of KA-induced epileptic rats, which was reversed after the use of curcumin. There was also a reduction in GSH levels in the brains of PTZ-induced rats; however, no change in GSH levels was observed after the use of exogenous antioxidants [80]. Regarding GSH levels in the hippocampus, our results were also confirmed by other studies that did not meet the eligibility criteria of this meta-analysis, showing that when the hippocampus is evaluated separately from the rest of the brain there is an increase in GSH after the use of antioxidant therapy [32,81,82,83].

It is known that neuronal GSH synthesis is dependent on the supply of glutamate and cysteine through the EAAC1 transporter found in the neuronal membrane [84]. Furthermore, neuronal GSH synthesis is supported by the supply of cysteine from the cleavage of GSH by astrocytes, which, in turn, depends on the transporters GLAST and GLT-1 to capture glutamate from the synaptic cleft [85]. Under normal conditions, when there is an excessive increase in glutamate in the synaptic cleft, transporters control glutamate levels and transport it to astrocytes and neurons [84,86]. A reduction in the expression of the glutamate transporters GLT-1 and GLAST has already been observed in epileptic animals induced by KA [87] and in a genetic model of epilepsy [88], in addition to verifying lethal spontaneous seizures in GLT-1-deficient mice [89,90]. In this context, failures in GLAST, GLT-1, and EAAC1 transporters in epilepsy, in addition to collaborating with the excitotoxicity of the glutamatergic system, provoke failures in the production of neuronal GSH, justifying the reduction of GSH in epileptic animals observed in the meta-analysis [28,91]. In addition, the results of meta-analyses on GSH indicate that the use of exogenous antioxidants collaborates with the increase in GSH levels which in turn may regulate the glutamatergic system, protecting against excitotoxicity induced by excess glutamate and inhibiting the intracellular influx of calcium ions [92,93].

Superoxide dismutase is another important enzyme in the endogenous antioxidant system that is capable of converting superoxide anions into hydrogen peroxide [94]. This study showed a reduction in SOD activity in the whole brain of epileptic animals compared to that in control animals, which was restored after the use of exogenous antioxidants. These data are in agreement with those of other studies that were not included in the meta-analysis because of eligibility criteria [79,95,96]. In addition to the whole brain, SOD and CAT activities were evaluated in the hippocampus. The meta-analysis showed that there was no difference in the activity of the two enzymes between epileptic animals and controls, or with the use of exogenous antioxidants. The findings of the SOD meta-analysis agree with those of Gao et al. (2014) [97]; however, this contradicts some published studies that showed a reduction in SOD activity in the hippocampi of epileptic animals compared with control animals, while SOD activity was restored after the use of exogenous antioxidants [32,82,98,99,100]. CAT activity is increased [97,98], while other studies point to a reduction in epileptic animals, with CAT activity being reversed after the use of exogenous antioxidants [32,99,100,101].

Both SOD and CAT activities in the hippocampus are expected to be reduced in epileptic animals, since overstimulation of NMDA receptors, in addition to causing an increase in RS production, also causes a reduction in the antioxidant system [93]. Given that GSH plays a key role in controlling RS, it is suggested that there is no synergy in the endogenous antioxidant system in the hippocampus; that is, GSH alone controls RS and does not require the participation of SOD and CAT. There is also the possibility that it is a reward system of the antioxidant system itself; that is, with an increase in oxidant agents, the activity of enzymes is increased. Another point regarding CAT activity is its association with circadian patterns. CAT activity in healthy animals varies over 24 h, with two peaks of activity [102]. This may have influenced the results of the meta-analysis since the primary articles did not show the times when the experimental activities took place. Furthermore, CAT activity is much lower in the brain than in the liver and kidneys [102], which may require more refined technologies to quantify CAT activity.

In the context of increased oxidant factors and the imbalance of antioxidant defenses observed in epilepsy, the study of NKA function is important. NKA plays a fundamental role in neuronal membranes, allowing for the maintenance of the ionic gradient [19]. Preclinical studies have reported that NKA activity is altered in epilepsy models [103], although it remains unchanged in the cerebellum of pilocarpine-induced rats, as suggested by Santos et al. 2010 [56]. In this meta-analysis, it was found that in the whole brain, hippocampus, and cortex, there was a reduction in NKA activity in epileptic animals compared with control animals [104,105,106]. This is because of at least one of the three situations described below. Lipid peroxidation of the plasma membrane is caused by increased MDA levels in epileptic animals. NKA is a transmembrane enzyme. Lipid peroxidation may disrupt the interaction between lipids and NKA, triggering a reduction in enzymatic activity [62], which may occur through nitration of the alpha subunit [105]. Meta-analysis data point to an increase in NO levels in epileptic animals, favoring the chemical reaction between NO and NKA and reducing their activity and sensitivity to reactive species, as NKA has sulfhydryl groups that are potentially oxidized, making the enzyme completely inactivated [107]. To avoid the total inactivity of NKA, there is a reversible process called S-glutathionylation, which consists of the formation of a disulfide bridge between GSH and a cysteine residue of the enzyme. The α-subunit of NKA contains 21 cysteine residues, 12 of which are available for glutathionylation. When glutathionylation occurs in Cys244, enzymatic activity is inhibited whereas in Cys454, Cys456, Cys458, and Cys459, it alters the signaling pathway modulated by NKA [108,109]. Furthermore, the level of glutathionylation has been shown to be dose- and time-dependent, causing complete inhibition of NKA [110], which is also dependent on enzymatic conformation, resulting in maximum glutathionylation in the E1 conformation of the alpha subunit of NKA [109]. Thus, the depletion of GSH observed in epileptic animals in this study may contribute to the reduction in S-glutathionylation, thereby reducing NKA activity.

In addition to the three situations analyzed, another possibility for the reduction in NKA activity in epileptic animals is the substrate ATP. The exacerbated consumption of ATP during convulsions, or even the reduction of its affinity for the enzyme, can lead to its inactivity [105]. This can occur only if S-glutathionylation fails, as this mechanism acts as a switch, preventing NKA from acting at very low ATP levels [110].

Another phenomenon that can occur is that glutamatergic neurotransmission may be impaired as a consequence of NKA malfunction. Previous studies have demonstrated that glutamate transporters and NKA are part of the same macromolecular complex and act synergistically in the regulation of glutamatergic neurotransmission [111,112]. Moreover, glutamate transport activity is regulated by NKA, which depends on sodium ions [113,114]. Selective inhibition of the α2 isoform of NKA is related to lower glutamate uptake [114]. Thus, malfunctioning NKA activity contributes to glutamatergic excitotoxicity as glutamate uptake is compromised [113].

When epileptic animals were treated with exogenous antioxidants, the meta-analysis revealed that changes in NKA activity were reversed in the three areas studied. These data are fundamental, as the normalization of NKA activity in epileptic animals treated with antioxidants provides adequate transport of glutamate to astrocytes, eliminating hyperstimulation of the glutamatergic system. It also induces neuronal GSH production, which is dependent on glutamate uptake by astrocytes and neurons [112]. Thus, the NKA/glutamate transporter complex has the potential to be a therapeutic target for patients with epilepsy.

To assess whether the improvement in biochemical parameters observed through the use of exogenous antioxidants was reflected in functional improvements in epileptic animals, we evaluated parameters such as seizure frequency, seizure latency, and mortality in treated animals. The meta-analysis gathered eight primary studies with 17 analyses and pointed out that the use of exogenous antioxidants increases the latency of seizures in epileptic animals. In addition to the primary studies used in this meta-analysis, several articles have reported similar results [33,54,55,58,60,80,100,115]. To complement the latency seizure data, the current study points to a reduction in both the number of seizures and mortality rate after treatment with external antioxidants. Thus, it is an effective therapy for reducing cell damage and protecting against changes resulting from epilepsy.

There has been an increase in research related to the use of antioxidants for various diseases, including epilepsy, with the objective of improving quality of life. In 2012, Goldberg-Stern et al. [35], in a pilot study, concluded that there was a reduction in the number of daytime seizures in patients receiving melatonin. This was also observed in patients receiving vitamin E [36]; however, patients receiving black seed oil showed no difference compared with those receiving placebo [116].

In summary, OS plays an important role in the development of epileptic seizures by affecting NKA activity and triggering behavioral changes. In view of this, antioxidant therapy undoes OS, normalizing biochemical data, as antioxidants scavenge free radicals, as they can reduce and donate hydrogen ions and mitigate the side effects of free radicals released during lipid peroxidation and cellular damage [71,117]. In addition, exogenous antioxidants are involved in reducing intracellular calcium levels, restoring mitochondrial function, restoring ATP production [62], and inhibiting NADPH oxidase [67].

Thus, antioxidant therapy has an anticonvulsant effect because normalizing the activity of NKA will allow the proper functioning of glutamate transporters, ceasing glutamatergic hyperstimulation, eliminating neuronal toxicity, suppressing seizures [69], and increasing latency [62]. Antioxidants act on the GABAergic system as antiepileptic drugs as they increase the levels of GABA neurotransmitters, ceasing the excitatory process [63,64,68,71,118].

Therefore, we can conclude that antioxidant therapy plays a neuroprotective role in experimental models. In addition, it can act as an adjunct in epilepsy treatment as it interferes with biochemical mechanisms, resulting in an increase in latency and a decrease in seizures and death.

Study Limitations

Despite an exhaustive search for primary studies, only a small number of studies have evaluated the use of antioxidants in epileptic animals and their association with NKA activity and OS.

The results of this study should be considered within the context of its limitations. One point to be raised is the high risk of bias in primary studies, which highlights a very high detection bias. We do not know if there is any interference with the sex of the animals since all primary studies exclusively used male animals. The high heterogeneity of most meta-analyses performed is due to factors such as different animal models (mice and rats), different types of antioxidants, as well as the duration, dosage, and limited number of studies. In addition, they use different epilepsy-inducing drugs, with variations in the doses of chemoconvulsants. Although we understand that the PILO, KA, and PTZ models are different, we analyze the data together because they show the same trend.

Despite the above, the meta-analyses presented in this article confirm the role of OS in the pathophysiology of epilepsy and its relationship with damage to NKA activity. Furthermore, the use of exogenous antioxidants significantly contributes to the balance between oxidative and antioxidant factors, normalizing NKA activity.

5. Conclusions

The results of this meta-analysis showed neural dysfunction in all models of epilepsy and in all brain regions analyzed. There was a decrease in antioxidant defenses such as GSH and SOD, and a decrease in NKA activity. In addition, there was an increase in oxidizing factors, such as NO, as well as an increase in lipid peroxidation markers, which may lead to cell damage. These parameters were associated with seizures and death. In this context, antioxidant therapy reversed the biochemical parameters altered by epilepsy and decreased the occurrence of seizures and animal mortality. Our findings confirm the neuroprotective effects of antioxidant therapy in epilepsy.

Author Contributions

A.D.d.M., V.A.F.F., Í.L.D., H.d.L.S., L.A.B. and L.E.D.d.C. performed the Selected the studies and extracted the data; A.D.d.M., V.A.F.F. and Í.L.D. performed the quality analysis of the studies; A.D.d.M., V.A.F.F., Í.L.D. and L.E.D.d.C. drafted and elaborated the figures and tables of the manuscript; A.D.d.M., H.d.L.S., L.A.B. and L.E.D.d.C. reviewed topics and discussed concepts in the manuscript. All authors have read and agreed to the published version of the manuscript.

Data Availability Statement

Published systematic review and PROSPERO (CRD42022356960).

Conflicts of Interest

The authors declare no conflict of interest.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Figures and Tables

Figure 1. Flow diagram of study selection. Search process using the PRISMA flow diagram.

Figure 2. Forest plot comparing NO levels in different parts of the brain. (A) Effect of epilepsy versus control; (B) effect of intervention with exogenous antioxidants (epileptics/antioxidants versus epileptics); 95% confidence interval (CI); inverse variance (IV); standard deviation (SD); green square represents effect size. A negative standardized mean difference (SMD) represents lower levels of NO, whereas a positive SMD represents higher levels of NO [57,62,64,65,68,70].

Figure 3. Forest plot comparing MDA levels in different parts of the brain. (A) Effect of epilepsy versus control; (B) effect of intervention with exogenous antioxidants (epileptics/antioxidants versus epileptics); 95% confidence interval (CI); inverse variance (IV); standard deviation (SD); green square represents effect size. A negative standardized mean difference (SMD) represents lower levels of MDA, whereas a positive SMD represents higher levels of MDA [54,57,61,62,64,65,67,68,69,70,71].

Figure 4. Forest plot comparing GSH levels in different parts of the brain. (A) Effect of epilepsy versus control; (B) effect of intervention with exogenous antioxidants (epileptics/antioxidants versus epileptics); 95% confidence interval (CI); inverse variance (IV); standard deviation (SD); green square represents effect size. A negative standardized mean difference (SMD) represents lower levels of GSH, whereas a positive SMD represents higher levels of GSH [20,57,62,64,65,68,70].

Figure 5. Forest plot comparing SOD activity in different parts of the brain. (A) Effect of epilepsy versus control; (B) effect of intervention with exogenous antioxidants (epileptics/antioxidants versus epileptics); 95% confidence interval (CI); inverse variance (IV); standard deviation (SD); green square represents effect size. A negative standardized mean difference (SMD) represents lower SOD activity, whereas a positive SMD represents higher SOD activity [54,64,65,67,68,69,70,71].

Figure 6. Forest plot comparing CAT activity in different parts of the brain. (A) Effect of epilepsy versus control; (B) effect of Intervention with exogenous antioxidants (epileptics/antioxidants versus epileptics); 95% confidence interval (CI); inverse variance (IV); standard deviation (SD); green square represents effect size. A negative standardized mean difference (SMD) represents lower CAT activity, whereas a positive SMD represents higher CAT activity [54,57,62,67,70].

Figure 7. Forest plot comparing NKA activity in different parts of the brain. (A) Effect of epilepsy versus control; (B) effect of intervention with exogenous antioxidants (epileptics/antioxidants versus epileptics); 95% confidence interval (CI); inverse variance (IV); standard deviation (SD); green square represents effect size. A negative standardized mean difference (SMD) represents lower NKA activity, whereas a positive SMD represents higher NKA activity [20,54,56,57,61,62,63,64,65,67,68,69,70,71].

Figure 8. Effect of antioxidant use on seizure-related outcomes and mortality. (A) Seizure frequency and mortality for use of antioxidants at all dosages in the primary studies. The data are expressed as percentages. (B) Seizure latency. Forest plot comparing antioxidant-treated epileptic animals and untreated epileptic animals. Confidence interval of 95% (CI); inverse variance (IV); standard deviation (SD); green square represents effect size. A negative standardized mean difference (SMD) represents a lower latency, whereas a positive SMD represents a higher latency [20,56,62,63,64,65,68,70].

Table 1

Risk of bias assessment using SYRCLE’s risk of bias tool for animal studies.

Study	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10
Oliveira 2004 [51]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Fighera 2006 [52]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Wilhelm 2009 [53]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Rambo 2009 [54]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Wilhelm 2010 [55]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Freitas 2010 [20]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Santos 2010 [56]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Ezz 2011 [57]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Bortolatto 2011 [58]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Souza 2013 [59]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Della-Pace 2013 [60]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Rambo 2013 [61]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Ahmed 2014 [62]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Pires 2015 [63]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Kandhare 2018 [64]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Zhang 2018 [65]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Tao 2020 [66]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Abd Allah 2021 [67]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Wang 2021 [68]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Vogt 2022 [69]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Alkhudhary 2022 [70]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]
Gad 2022 [71]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]	[Image omitted. Please see PDF.]

Note: low risk of bias ([Image omitted. Please see PDF.]); high risk of bias ([Image omitted. Please see PDF.]); unclear risk of bias ([Image omitted. Please see PDF.]). Questions Q1, Q2, and Q3 relate to selection bias; Q4 and Q5 relate to performance bias; Q6 and Q7 relate to detection bias; and questions Q8, Q9, and Q10 relate to attrition, information, and other biases, respectively. Details are provided in Supplementary Data N° 1.

Table 2

Description of the animals, antioxidants and biochemical outcomes of the epilepsy and epilepsy + antioxidants studies.

Reference	Brain AreasSample Size	Animal ModelCharacteristics	Antioxidant	Results
* Oliveira et al., 2004 [51]	Striatum10–14	Wistar Rats/270–300 gPTZ 1.8 μmol/2 μL Intraestrial	Ascorbic acid (30, 100 or 300 mg/Kg)/i.p. 30 min before PTZ	Epilepsy: NKA ↓; PCA ↑Epilepsy + antioxidants: NKA ↑ (1); n.s (2);PCA ↓ (1); n.s (2)
* Fighera et al., 2006 [52]	Striatum6–8	Wistar Rats/270–300 gPTZ 1.8 µmol/2 µL Intraestrial	GM1 ganglioside 50 mg/kg/i.p. 30 min before the injection of PTZ	Epilepsy: NKA ↓;PCA ↑; MDA ↑Epilepsy + antioxidants: NKA ↑; PCA ↓; MDA ↓
* Wilhelm et al., 2009 [53]	Whole Brain8–12	Wistar Rats/40–50 gPILO 400 mg/Kg/i.p.	3-ASP (10, 25 or 50 mg/Kg)/Oral 30 min before of PILO	Epilepsy: NKA ↓; GPx ↓; GST ↑; SOD ↓; CAT ↑; RS ↑Epilepsy + antioxidants: NKA ↑; GPx n.s; GST n.s;SOD ↑ (1)/n.s (2); CAT ↓ (2)/n.s (1); RS ↓
Rambo et al., 2009 [54]	Hippocampus8–10	Wistar Rats/250–300 gPTZ (30 or 60 mg/Kg)/i.p.	Creatine 300 mg/Kg Oral gavage 6 weeks	Epilepsy: NKA ↓; SOD n.s; CAT ↓ (1)/n.s (1); MDA ↑; PCA ↑Epilepsy + antioxidants: NKA ↑; SOD ↑ (1)/n.s (1);CAT ↑ (1)/n.s (1); MDA ↓; PCA ↓ (1)/n.s
* Wilhelm et al., 2010 [55]	Whole Brain5–8	Swiss Mice/25–35 g PILO 400 mg/Kg/i.p.	BPD (1, 5, 10, 25, 50 or 100 mg/Kg) Oral gavage 30 min before PILO	Epilepsy: NKA ↓; GPx ↓; GST ↑; CAT ↑; MDA↑; RS ↑Epilepsy + antioxidants: NKA ↑; GPx n.s; GST ↑(1)/n.s (5); CAT n.s; MDA ↓ (4)/n.s (2); RS ↓ (5)/n.s (1)
Freitas, 2010 [20]	Hippocampus5–7	Wistar Rats/250–280 g PILO 400 mg/Kg/i.p.	LA 10 mg/Kg/i.p./30 min before PILO	Epilepsy: NKA ↓; GPx ↑; GSH ↓; GR n.sEpilepsy + antioxidants: NKA ↑; GPx ↑; GSH ↑; GR n.s
Santos et al., 2010 [56]	Hippocampus5–7	Wistar Rats/250–280 g PILO 400 mg/Kg/i.p.	LA 10 mg/Kg/i.p./30 min before PILO	Epilepsy: NKA ↓Epilepsy + antioxidants: NKA ↑
	Striatum5–7			Epilepsy: NKA ↓Epilepsy + antioxidants: NKA ↑
	Cortex5–7			Epilepsy: NKA n.sEpilepsy + antioxidants: NKA n.s
	Cerebellum5–7			Epilepsy: NKA n.sEpilepsy + antioxidants: NKA n.s
Ezz et al., 2011 [57]	Hippocampus5–7	Wistar Rats/200–250 gPILO 380 mg/Kg/i.p.	Curcumin 80 mg/Kg or Nigella sativa oil (NSO) 4 mL/Kg/Orally/21 days	Epilepsy: NKA ↓; GSH ↓; CAT ↓; NO ↑; MDA n.sEpilepsy + antioxidants: NKA and GSH: ↑ (1)/n.s (1); CAT and NO: ↓ (1)/n.s (1); MDA n.s
* Bortolatto et al., 2011 [58]	Hippocampus8–10	Wistar Rats/200–300 g KA 10 mg/Kg/i.p.	DTDS (50 or 100 mg/Kg)/Oral by gavage 1 h after the animals received KA	Epilepsy: NKA ↑; GPx n.s; PCA ↑; RS ↑Epilepsy + antioxidants: NKA ↓; GPx n.s; PCA ↓; RS ↓
	Cortex8–10			Epilepsy: NKA ↑; GPx, PCA and RS: n.sEpilepsy + antioxidants: NKA ↓; GPx, PCA and RS: n.s
* Souza et al., 2013 [59]	Cortex7–8	Wistar Rats/270–300 g PTZ 60 mg/Kg/i.p.	Caffeine 6 mg/Kg/Oral by gavage 60 min before PTZ	Epilepsy: NKA ↓; GSH ↓; MDA↑Epilepsy + antioxidants: NKA ↑; GSH ↑; MDA ↓
* Della-Pace et al., 2013 [60]	Cortex8–9	Swiss Mice/25–35 g PTZ 80 mg/Kg/i.p.	TTHL 30 mg/Kg/Orally by gavage/60 min before PTZ	Epilepsy: NKA ↓; MDA↑; PCA ↑Epilepsy + antioxidants: NKA ↑; MDA ↓; PCA ↓
Rambo et al., 2013 [61]	Cortex5–7	Wistar Rats/270–300 g PTZ (30, 45 or 60 mg/Kg)/i.p.	Creatine 300 mg/Kg/Orally/45 min before PTZ	Epilepsy: NKA ↓; MDA↑; PCA ↑Epilepsy + antioxidants: NKA ↑; MDA ↓; PCA ↓
Ahmed, 2014 [62]	Hippocampus10	Sprague-Dawley Rats/250–280 g PILO 400 mg/Kg/i.p.	Idebenone (50, 100 or 200 mg/kg) i.p./3 successive days	Epilepsy: NKA ↓; GSH ↓; CAT ↑; NO ↑; MDA↑Epilepsy + antioxidants: NKA ↑ (2)/n.s (1); GSH ↑ (1)/n.s (2); CAT, NO and MDA: ↓ (2)/n.s (1)
Pires et al., 2015 [63]	Hippocampus10	Swiss Mice/25–30 g/PTZ 60 mg/Kg or PILO400 mg/Kg/i.p	CA 100 mg/Kg/i.p./30 min before PILO or PTZ	Epilepsy: NKA ↓Epilepsy + antioxidants: NKA ↑
Kandhare et al., 2018 [64]	Whole Brain6	Swiss Mice/18–22 g/PTZ 90 mg/Kg/i.p.	Morin (10, 20 or 40 mg/Kg)/i.p./45 min before PTZ	Epilepsy: NKA ↓; GSH ↓; SOD ↓; NO ↑; MDA↑Epilepsy + antioxidants: NKA and GSH: ↑ (2)/n.s (1); SOD ↑; NO and MDA: ↓ (2)/n.s (1)
Zhang et al., 2018 [65]	Whole Brain6	Swiss Mice/18–22 g/PTZ 90 mg/Kg/i.p.	TEMPOL (50, 100 or 200 mg/Kg)/Oral45 min before PTZ	Epilepsy: NKA ↓; GSH ↓; SOD ↓; NO ↑; MDA ↑Epilepsy + antioxidants: NKA ↑ (2)/n.s (1); GSH ↑; SOD ↑; NO and MDA: ↓ (2)/n.s (1)
* Tao et al., 2020 [66]	Whole Brain5–6	Swiss Mice/18–22 g PTZ 90 mg/Kg/i.p.	PA (50, 100 or 200 mg/Kg)/i.p. 45 min before PTZ	Epilepsy: NKA ↓; GSH ↓; SOD ↓; NO ↑; MDA↑Epilepsy + antioxidants: NO and MDA: ↓ (2)/n.s (1);NKA, GSH and SOD: ↑ (2)/n.s (1)
Adb Allah et al., 2021 [67]	Hippocampus6	Wistar Rats/150–170 g PILO 300 mg/kg/i.p.	M. officinalis extract (MOE)/250 mg/Kg Oral for 2 weeks	Epilepsy: NKA ↓; SOD ↓; CAT ↓; MDA↑Epilepsy + antioxidants: NKA ↑; SOD ↑; CAT ↑; MDA ↓
Wang et al., 2021 [68]	Whole Brain6	Swiss Mice/20–30 gPTZ 70 mg/Kg/i.p.	EE-ATF (50, 75 or 100 mg/Kg)/Oral30 min before PTZ	Epilepsy: NKA ↓; GSH ↓; SOD ↓; NO ↑; MDA ↑ Epilepsy + antioxidants: NKA ↑; SOD ↑; NO ↓; MDA ↓
Vogt et al., 2022 [69]	Hippocampus7	Swiss Mice/25–35 g PTZ 35 mg/Kg/i.p.	QTCA-1 10 mg/kg by gavage 30 min before PTZ	Epilepsy: NKA ↓; SOD ↑; MDA ↑; RS ↑Epilepsy + antioxidants: NKA ↑; SOD ↓; MDA ↓; RS ↓
	Cortex7			Epilepsy: NKA ↓; SOD ↑; MDA↑; RS ↑Epilepsy + antioxidants: NKA ↑; SOD ↓; MDA ↓; RS ↓
Alkhudhary et al., 2022 [70]	Hippocampus7	Wistar Rats/180–200 gPTZ 60 mg/Kg/i.p.	ESE (250 mg/Kg)/Oral/for 7 days	Epilepsy: NKA ↓; GSH ↓; SOD ↓; CAT ↓; GPx ↓; GR↓; NO ↑; MDA ↑ Epilepsy + antioxidants: NKA ↑; GSH ↑; SOD ↑; CAT ↑; GPx ↑; GR ↑; NO ↓; MDA ↓
Gad et al., 2022 [71]	Whole Brain8	Sprague-Dawley Rats/150–180 g/PILO 300 mg/Kg/i.p.	Passiflora extract 200 mg/Kg/intragastric intubation/4 weeks	Epilepsy: NKA ↓; SOD ↓; CAT ↓; GR ↓; MDA↑Epilepsy + antioxidants: NKA ↑; SOD ↑; CAT ↑; GR ↑; MDA n.s

Note: Carvacryl acetate (CA); 1-(7-chloroquinolin-4-yl)-5-methyl-N-phenyl-1H-1,2,3-triazole-4-carboxamide (QTCA-1); Ethanolic extract of A.tsaoko fruits (EE-ATF); 3-alkynyl selenophene (3-ASP); (E)-2-benzylidene-4-phenyl-1,3-diselenole (BPD); 4-Hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPOL); Phyllathin amarus extract (PA); Echinops spinosus extract (ESE); Lipoic acid (LA); TTHL (Triterpene 3β, 6β, 16β-trihidroxilup-20(29)-ene); DTDS (2,2′-Dithienyl diselenide); intraperitoneal (i.p.). * Studies excluded from the meta-analysis; ↑ (significant increase); ↓ (significant decrease); n.s. (non-significant data), considering p < 0.05.

Table 3

Summary of meta-analyses.

Outcomes	Brain Part	Epileptics	Epileptics/Antioxidant
GSH	WB, HIP	↓	↑
SOD	WB, HIP	↓, n.s	↑, n.s
CAT	HIP	n.s	n.s
NO	WB, HIP	↑	↓
MDA	WB, HIP, COR	↑	↓
NKA	WB, HIP, COR	↓	↑
Latency			↑

Note: ↑ (significant increase); ↓ (significant decrease); n.s (non-significant data), considering p < 0.05. Whole brain (WB), hippocampus (HIP), cortex (COR), Epileptics (untreated epileptic animals), Epileptics/Antioxidant (epileptic animals using antioxidant therapy).

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/antiox12071397/s1, Supplementary Data N° 1: Risk of bias assessment; Supplementary Data N° 2: The brain area under study and the outcome assessed.

References

1. Thijs, R.D.; Surges, R.; O’Brien, T.J.; Sander, J.W. Epilepsy in Adults. Lancet; 2019; 393, pp. 689-701. [DOI: https://dx.doi.org/10.1016/S0140-6736(18)32596-0]

2. Fisher, R.S.; Van Emde Boas, W.; Blume, W.; Elger, C.; Genton, P.; Lee, P.; Engel, J. Epileptic Seizures and Epilepsy: Definitions Proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia; 2005; 46, pp. 470-472. [DOI: https://dx.doi.org/10.1111/j.0013-9580.2005.66104.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15816939]

3. Mao, X.Y.; Zhou, H.H.; Jin, W.L. Redox-Related Neuronal Death and Crosstalk as Drug Targets: Focus on Epilepsy. Front. Neurosci.; 2019; 13, 512. [DOI: https://dx.doi.org/10.3389/fnins.2019.00512] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31191222]

4. Geronzi, U.; Lotti, F.; Grosso, S. Oxidative Stress in Epilepsy. Expert Rev. Neurother.; 2018; 18, pp. 427-434. [DOI: https://dx.doi.org/10.1080/14737175.2018.1465410]

5. Realmuto, S.; Zummo, L.; Cerami, C.; Agrò, L.; Dodich, A.; Canessa, N.; Zizzo, A.; Fierro, B.; Daniele, O. Social Cognition Dysfunctions in Patients with Epilepsy: Evidence from Patients with Temporal Lobe and Idiopathic Generalized Epilepsies. Epilepsy Behav.; 2015; 47, pp. 98-103. [DOI: https://dx.doi.org/10.1016/j.yebeh.2015.04.048] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25982884]

6. Wu, Y.; Wang, Y.; Wu, Y.; Li, T.; Wang, W. Salidroside Shows Anticonvulsant and Neuroprotective Effects by Activating the Nrf2-ARE Pathway in a Pentylenetetrazol-Kindling Epileptic Model. Brain Res. Bull.; 2020; 164, pp. 14-20. [DOI: https://dx.doi.org/10.1016/j.brainresbull.2020.08.009]

7. Yang, D.Q.; Zuo, Q.N.; Wang, T.; Xu, D.; Lian, L.; Gao, L.J.; Wan, C.; Chen, L.; Wen, F.Q.; Shen, Y.C. Mitochondrial-Targeting Antioxidant SS-31 Suppresses Airway Inflammation and Oxidative Stress Induced by Cigarette Smoke. Oxid. Med. Cell. Longev.; 2021; 2021, 6644238. [DOI: https://dx.doi.org/10.1155/2021/6644238]

8. Checa, J.; Aran, J.M. Reactive Oxygen Species: Drivers of Physiological and Pathological Processes. J. Inflamm. Res.; 2020; 2020, pp. 1057-1073. [DOI: https://dx.doi.org/10.2147/JIR.S275595]

9. Sharifi-Rad, M.; Anil Kumar, N.V.; Zucca, P.; Varoni, E.M.; Dini, L.; Panzarini, E.; Rajkovic, J.; Tsouh Fokou, P.V.; Azzini, E.; Peluso, I. et al. Lifestyle, Oxidative Stress, and Antioxidants: Back and Forth in the Pathophysiology of Chronic Diseases. Front. Physiol.; 2020; 11, 694. [DOI: https://dx.doi.org/10.3389/fphys.2020.00694]

10. Fiorito, G.; Vlaanderen, J.; Polidoro, S.; Gulliver, J.; Galassi, C.; Ranzi, A.; Krogh, V.; Grioni, S.; Agnoli, C.; Sacerdote, C. et al. Oxidative Stress and Inflammation Mediate the Effect of Air Pollution on Cardio- and Cerebrovascular Disease: A Prospective Study in Nonsmokers. Environ. Mol. Mutagen.; 2018; 59, pp. 234-246. [DOI: https://dx.doi.org/10.1002/em.22153]

11. Birben, E.; Sahiner, U.M.; Sackesen, C.; Erzurum, S.; Kalayci, O. Oxidative Stress and Antioxidant Defense. World Allergy Organ. J.; 2012; 5, pp. 9-19. [DOI: https://dx.doi.org/10.1097/WOX.0b013e3182439613]

12. Kovac, S.; Kostova, A.T.D.; Herrmann, A.M.; Melzer, N.; Meuth, S.G.; Gorji, A. Metabolic and Homeostatic Changes in Seizures and Acquired Epilepsy—Mitochondria, Calcium Dynamics and Reactive Oxygen Species. Int. J. Mol. Sci.; 2017; 18, 1935. [DOI: https://dx.doi.org/10.3390/ijms18091935]

13. Szabó, C.; Ischiropoulos, H.; Radi, R. Peroxynitrite: Biochemistry, Pathophysiology and Development of Therapeutics. Nat. Rev. Drug Discov.; 2007; 6, pp. 662-680. [DOI: https://dx.doi.org/10.1038/nrd2222]

14. Moncada, S.; Bolaños, J.P. Nitric Oxide, Cell Bioenergetics and Neurodegeneration. J. Neurochem.; 2006; 97, pp. 1676-1689. [DOI: https://dx.doi.org/10.1111/j.1471-4159.2006.03988.x]

15. Cobley, J.N.; Fiorello, M.L.; Bailey, D.M. 13 Reasons Why the Brain Is Susceptible to Oxidative Stress. Redox. Biol.; 2018; 15, pp. 490-503. [DOI: https://dx.doi.org/10.1016/j.redox.2018.01.008]

16. McCoy, C.R.; Sabbagh, M.N.; Huaman, J.P.; Pickrell, A.M.; Clinton, S.M. Oxidative Metabolism Alterations in the Emotional Brain of Anxiety-Prone Rats. Prog. Neuropsychopharmacol. Biol. Psychiatry; 2019; 95, 109706. [DOI: https://dx.doi.org/10.1016/j.pnpbp.2019.109706] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/31330216]

17. Dobrota, D.; Matejovicova, M.; Kurella, E.G.; Boldyrev, A.A. Na/K-ATPase under Oxidative Stress: Molecular Mechanisms of Injury. Cell. Mol. Neurobiol.; 1999; 19, pp. 141-149. [DOI: https://dx.doi.org/10.1023/A:1006928927480] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/10079973]

18. Farrell, J.S.; Wolff, M.D.; Teskey, G.C. Neurodegeneration and Pathology in Epilepsy: Clinical and Basic Perspectives. Neurodegenerative Diseases; Advances in Neurobiology Springer: Cham, Switzerland, 2017; Volume 15, pp. 317-334. [DOI: https://dx.doi.org/10.1007/978-3-319-57193-5_12]

19. Blanco, G.; Mercer, R.W. Isozymes of the Na-K-ATPase: Heterogeneity in Structure, Diversity in Function. Am. J. Physiol.; 1998; 44, pp. 633-650. [DOI: https://dx.doi.org/10.1152/ajprenal.1998.275.5.F633] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9815123]

20. De Freitas, R.M. Lipoic Acid Alters δ-Aminolevulinic Dehydratase, Glutathione Peroxidase and Na⁺,K⁺-ATPase Activities and Glutathione-Reduced Levels in Rat Hippocampus after Pilocarpine-Induced Seizures. Cell. Mol. Neurobiol.; 2010; 30, pp. 381-387. [DOI: https://dx.doi.org/10.1007/s10571-009-9460-9]

21. Grisar, A’.B.T.; Guillaume, A’.D.; Delgado-Escueta, A.V. Contribution of Na +,K +-ATPase to Focal Epilepsy: A Brief Review. Epilepsy Res.; 1992; 12, pp. 141-149. [DOI: https://dx.doi.org/10.1016/0920-1211(92)90034-Q]

22. Barbosa, K.; Costa, N.; Alfenas, R.; DE Paula, S.; Minim, V.; Bressan, J. Revista de Nutrição Oxidative Stress: Concept, Implications and Modulating Factors. Rev. Nutr.; 2010; 23, pp. 629-643. [DOI: https://dx.doi.org/10.1590/S1415-52732010000400013]

23. Gaby, A.R. Natural Approaches to Epilepsy. Altern. Med. Rev.; 2007; 12, 9. [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/17397265]

24. Forman, H.J.; Zhang, H. Targeting Oxidative Stress in Disease: Promise and Limitations of Antioxidant Therapy. Nat. Rev. Drug Discov.; 2021; 20, pp. 689-709. [DOI: https://dx.doi.org/10.1038/s41573-021-00233-1] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34194012]

25. Lv, C.; Maharjan, S.; Wang, Q.; Sun, Y.; Han, X.; Wang, S.; Mao, Z.; Xin, Y.; Zhang, B. α-Lipoic Acid Promotes Neurological Recovery after Ischemic Stroke by Activating the Nrf2/HO-1 Pathway to Attenuate Oxidative Damage. Cell. Physiol. Biochem.; 2017; 43, pp. 1273-1287. [DOI: https://dx.doi.org/10.1159/000481840] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28992629]

26. Kasote, D.M.; Hegde, M.V.; Katyare, S.S. Mitochondrial Dysfunction in Psychiatric and Neurological Diseases: Cause(s), Consequence(s), and Implications of Antioxidant Therapy. BioFactors; 2013; 39, pp. 392-406. [DOI: https://dx.doi.org/10.1002/biof.1093]

27. Haghnejad Azar, A.; Oryan, S.; Bohlooli, S.; Panahpour, H. Alpha-Tocopherol Reduces Brain Edema and Protects Blood-Brain Barrier Integrity Following Focal Cerebral Ischemia in Rats. Med. Princ. Pract.; 2017; 26, pp. 17-22. [DOI: https://dx.doi.org/10.1159/000450648]

28. Wang, Y.; Chen, M.; Zhang, Y.; Huo, T.; Fang, Y.; Jiao, X.; Yuan, M.; Jiang, H. Effects of Realgar on GSH Synthesis in the Mouse Hippocampus: Involvement of System XAG−, System XC−, MRP-1 and Nrf2. Toxicol. Appl. Pharmacol.; 2016; 308, pp. 91-101. [DOI: https://dx.doi.org/10.1016/j.taap.2016.07.006]

29. Taghizadeh, M.; Tamtaji, O.R.; Dadgostar, E.; Daneshvar Kakhaki, R.; Bahmani, F.; Abolhassani, J.; Aarabi, M.H.; Kouchaki, E.; Memarzadeh, M.R.; Asemi, Z. The Effects of Omega-3 Fatty Acids and Vitamin E Co-Supplementation on Clinical and Metabolic Status in Patients with Parkinson’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial. Neurochem. Int.; 2017; 108, pp. 183-189. [DOI: https://dx.doi.org/10.1016/j.neuint.2017.03.014]

30. Shinto, L.; Quinn, J.; Montine, T.; Dodge, H.H.; Woodward, W.; Baldauf-Wagner, S.; Waichunas, D.; Bumgarner, L.; Bourdette, D.; Silbert, L. et al. A Randomized Placebo-Controlled Pilot Trial of Omega-3 Fatty Acids and Alpha Lipoic Acid in Alzheimer’s Disease. J. Alzheimer’s Dis.; 2014; 38, pp. 111-120. [DOI: https://dx.doi.org/10.3233/JAD-130722]

31. Gutzmann, H.; Hadler, D. Sustained Efficacy and Safety of Idebenone in the Treatment of Alzheimer’s Disease: Update on a 2-Year Double-Blind Multi Centre Study. Alzheimer’s Disease-From Basic Research to Clinical Applications; Springer: Vienna, Austria, 1998.

32. Essawy, A.E.; El-Sayed, S.A.; Tousson, E.; Abd El-gawad, H.S.; Alhasani, R.H.; Abd Elkader, H.T.A.E. Anti-Kindling Effect of Ginkgo Biloba Leaf Extract and L-Carnitine in the Pentylenetetrazol Model of Epilepsy. Environ. Sci. Pollut. Res.; 2022; 29, pp. 48573-48587. [DOI: https://dx.doi.org/10.1007/s11356-022-19251-6]

33. Asgharzade, S.; Rabiei, Z.; Rabiei, S.; Bijad, E.; Rafieian-Kopaei, M. Therapeutic Effects of Oleuropein in Improving Seizure, Oxidative Stress and Cognitive Disorder in Pentylenetetrazole Kindling Model of Epilepsy in Mice. Iran. J. Pharm. Res.; 2020; 19, pp. 98-110. [DOI: https://dx.doi.org/10.22037/ijpr.2019.14212.12209] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32922473]

34. Costello, D.J.; Delanty, N. Oxidative Injury in Epilepsy: Potential for Antioxidant Therapy?. Expert Rev. Neurother.; 2004; 4, pp. 541-553. [DOI: https://dx.doi.org/10.1586/14737175.4.3.541] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/15853548]

35. Goldberg-Stern, H.; Oren, H.; Peled, N.; Garty, B.Z. Effect of Melatonin on Seizure Frequency in Intractable Epilepsy: A Pilot Study. J. Child Neurol.; 2012; 27, pp. 1524-1528. [DOI: https://dx.doi.org/10.1177/0883073811435916] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22378657]

36. Mehvari, J.; Motlagh, F.; Najafi, M.; Ghazvini, M.A.; Naeini, A.; Zare, M. Effects of Vitamin E on Seizure Frequency, Electroencephalogram Findings, and Oxidative Stress Status of Refractory Epileptic Patients. Adv. Biomed. Res.; 2016; 5, 36. [DOI: https://dx.doi.org/10.4103/2277-9175.178780] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27099849]

37. Gupta, M.; Gupta, Y.K.; Agarwal, S.; Aneja, S.; Kohli, K. A Randomized, Double-Blind, Placebo Controlled Trial of Melatonin Add-on Therapy in Epileptic Children on Valproate Monotherapy: Effect on Glutathione Peroxidase and Glutathione Reductase Enzymes. Br. J. Clin. Pharmacol.; 2004; 58, pp. 542-547. [DOI: https://dx.doi.org/10.1111/j.1365-2125.2004.02210.x]

38. Raju, G.B.; Behari, M.; Prasad, K.; Ahuja, G.K. Randomized, Double-Blind, Placebo-Controlled, Clinical Trial of D-a-Tocopherol (Vitamin E) as Add-on Therapy in Uncontrolled Epilepsy. Epilepsia; 1994; 35, pp. 368-372. [DOI: https://dx.doi.org/10.1111/j.1528-1157.1994.tb02446.x]

39. Kim, J.E.; Cho, K.O. The Pilocarpine Model of Temporal Lobe Epilepsy and EEG Monitoring Using Radiotelemetry System in Mice. J. Vis. Exp.; 2018; 132, e56831. [DOI: https://dx.doi.org/10.3791/56831]

40. Lévesque, M.; Avoli, M. The Kainic Acid Model of Temporal Lobe Epilepsy. Neurosci. Biobehav. Rev.; 2013; 37, pp. 2887-2899. [DOI: https://dx.doi.org/10.1016/j.neubiorev.2013.10.011]

41. Raol, Y.H.; Brooks-Kayal, A.R. Experimental Models of Seizures and Epilepsies. Progress in Molecular Biology and Translational Science; Elsevier B.V.: Amsterdam, The Netherlands, 2012; Volume 105, pp. 57-82. [DOI: https://dx.doi.org/10.1016/B978-0-12-394596-9.00003-2]

42. Turski, L.; Ikonomidou, C.; Turski, W.A.; Bortolotto, Z.A.; Cavalheiro, E.A. Review: Cholinergic Mechanisms and Epileptogenesis. The Seizures Induced by Pilocarpine: A Novel Experimental Model of Intractable Epilepsy. Synapse; 1989; 3, pp. 154-171. [DOI: https://dx.doi.org/10.1002/syn.890030207]

43. Tashakori-Miyanroudi, M.; Ramazi, S.; Hashemi, P.; Nazari-Serenjeh, M.; Baluchnejadmojarad, T.; Roghani, M. Acetyl-L-Carnitine Exerts Neuroprotective and Anticonvulsant Effect in Kainate Murine Model of Temporal Lobe Epilepsy. J. Mol. Neurosci.; 2022; 72, pp. 1224-1233. [DOI: https://dx.doi.org/10.1007/s12031-022-01999-8] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35320462]

44. Löscher, W. Preclinical Assessment of Proconvulsant Drug Activity and Its Relevance for Predicting Adverse Events in Humans. Eur. J. Pharmacol.; 2009; 610, pp. 1-11. [DOI: https://dx.doi.org/10.1016/j.ejphar.2009.03.025] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19292981]

45. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E. et al. The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews. BMJ; 2021; 372, n71. [DOI: https://dx.doi.org/10.1136/bmj.n71] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/33782057]

46. Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan-a Web and Mobile App for Systematic Reviews. Syst. Rev.; 2016; 5, 210. [DOI: https://dx.doi.org/10.1186/s13643-016-0384-4] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27919275]

47. Rohatgi, A. Web Plot Digitizer, Version 4.5; EUA: California. 2021; Available online: https://automeris.io/WebPlotDigitizer/ (accessed on 5 April 2022).

48. Cochrane Collaboration. Review Manager (RevMan); Version 5.4 Cochrane Collaboration: London, UK, 2020.

49. Riley, R.D.; Higgins, J.P.; Deeks’, J.J. Interpretation of Random Effects Meta-Analyses. BMJ; 2011; 342, d549. [DOI: https://dx.doi.org/10.1136/bmj.d549]

50. Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions|Cochrane Training. Available online: https://training.cochrane.org/handbook (accessed on 4 July 2022).

51. Schneider Oliveira, M.; Flávia Furian, A.; Freire Royes, L.F.; Rechia Fighera, M.; De Carvalho Myskiw, J.; Gindri Fiorenza, N.; Mello, C.F. Ascorbate Modulates Pentylenetetrazol-Induced Convulsions Biphasically. Neuroscience; 2004; 128, pp. 721-728. [DOI: https://dx.doi.org/10.1016/j.neuroscience.2004.07.012]

52. Fighera, M.R.; Royes, L.F.F.; Furian, A.F.; Oliveira, M.S.; Fiorenza, N.G.; Frussa-Filho, R.; Petry, J.C.; Coelho, R.C.; Mello, C.F. GM1 Ganglioside Prevents Seizures, Na⁺,K⁺-ATPase Activity Inhibition and Oxidative Stress Induced by Glutaric Acid and Pentylenetetrazole. Neurobiol. Dis.; 2006; 22, pp. 611-623. [DOI: https://dx.doi.org/10.1016/j.nbd.2006.01.002]

53. Wilhelm, E.A.; Jesse, C.R.; Bortolatto, C.F.; Nogueira, C.W.; Savegnago, L. Anticonvulsant and Antioxidant Effects of 3-Alkynyl Selenophene in 21-Day-Old Rats on Pilocarpine Model of Seizures. Brain Res. Bull.; 2009; 79, pp. 281-287. [DOI: https://dx.doi.org/10.1016/j.brainresbull.2009.03.006]

54. Rambo, L.M.; Ribeiro, L.R.; Oliveira, M.S.; Furian, A.F.; Lima, F.D.; Souza, M.A.; Silva, L.F.A.; Retamoso, L.T.; Corte, C.L.D.; Puntel, G.O. et al. Additive Anticonvulsant Effects of Creatine Supplementation and Physical Exercise against Pentylenetetrazol-Induced Seizures. Neurochem. Int.; 2009; 55, pp. 333-340. [DOI: https://dx.doi.org/10.1016/j.neuint.2009.04.007]

55. Wilhelm, E.A.; Jesse, C.R.; Roman, S.S.; Bortolatto, C.F.; Nogueira, C.W. Anticonvulsant Effect of (E)-2-Benzylidene-4-Phenyl-1,3-Diselenole in a Pilocarpine Model in Mice. Life Sci.; 2010; 87, pp. 620-627. [DOI: https://dx.doi.org/10.1016/j.lfs.2010.09.022]

56. de Sales Santos, Í.M.; da Rocha Tomé, A.; Feitosa, C.M.; de Souza, G.F.; Feng, D.; de Freitas, R.M.; Jordán, J. Lipoic Acid Blocks Seizures Induced by Pilocarpine via Increases in δ-Aminolevulinic Dehydratase and Na⁺, K⁺-ATPase Activity in Rat Brain. Pharmacol. Biochem. Behav.; 2010; 95, pp. 88-91. [DOI: https://dx.doi.org/10.1016/j.pbb.2009.12.011]

57. Aboul Ezz, H.S.; Khadrawy, Y.A.; Noor, N.A. The Neuroprotective Effect of Curcumin and Nigella Sativa Oil against Oxidative Stress in the Pilocarpine Model of Epilepsy: A Comparison with Valproate. Neurochem. Res.; 2011; 36, pp. 2195-2204. [DOI: https://dx.doi.org/10.1007/s11064-011-0544-9]

58. Bortolatto, C.F.; Jesse, C.R.; Wilhelm, E.A.; Ribeiro, L.R.; Rambo, L.M.; Royes, L.F.F.; Roman, S.S.; Nogueira, C.W. Protective Effect of 2,2′-Dithienyl Diselenide on Kainic Acid-Induced Neurotoxicity in Rat Hippocampus. Neuroscience; 2011; 193, pp. 300-309. [DOI: https://dx.doi.org/10.1016/j.neuroscience.2011.07.038]

59. Souza, M.A.; Mota, B.C.; Gerbatin, R.R.; Rodrigues, F.S.; Castro, M.; Fighera, M.R.; Royes, L.F.F. Antioxidant Activity Elicited by Low Dose of Caffeine Attenuates Pentylenetetrazol-Induced Seizures and Oxidative Damage in Rats. Neurochem. Int.; 2013; 62, pp. 821-830. [DOI: https://dx.doi.org/10.1016/j.neuint.2013.02.021]

60. Della-Pace, I.D.; Rambo, L.M.; Ribeiro, L.R.; Saraiva, A.L.L.; De Oliveira, S.M.; Silva, C.R.; Villarinho, J.G.; Rossato, M.F.; Ferreira, J.; De Carvalho, L.M. et al. Triterpene 3β, 6β, 16β Trihidroxilup-20(29)-Ene Protects against Excitability and Oxidative Damage Induced by Pentylenetetrazol: The Role of Na⁺, K⁺-ATPase Activity. Neuropharmacology; 2013; 67, pp. 455-464. [DOI: https://dx.doi.org/10.1016/j.neuropharm.2012.10.022]

61. Rambo, L.M.; Ribeiro, L.R.; Della-Pace, I.D.; Stamm, D.N.; Da Rosa Gerbatin, R.; Prigol, M.; Pinton, S.; Nogueira, C.W.; Furian, A.F.; Oliveira, M.S. et al. Acute Creatine Administration Improves Mitochondrial Membrane Potential and Protects against Pentylenetetrazol-Induced Seizures. Amino Acids; 2013; 44, pp. 857-868. [DOI: https://dx.doi.org/10.1007/s00726-012-1408-6]

62. Ahmed, M.A.E. Neuroprotective Effects of Idebenone against Pilocarpine-Induced Seizures: Modulation of Antioxidant Status, DNA Damage and Na⁺, K⁺-ATPase Activity in Rat Hippocampus. Neurochem. Res.; 2014; 39, pp. 394-402. [DOI: https://dx.doi.org/10.1007/s11064-014-1236-z] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24414170]

63. Pires, L.F.; Costa, L.M.; de Almeida, A.A.C.; Silva, O.A.; Cerqueira, G.S.; de Sousa, D.P.; Pires, R.M.C.; Satyal, P.; de Freitas, R.M. Neuropharmacological Effects of Carvacryl Acetate on δ-Aminolevulinic Dehydratase, Na⁺, K⁺-ATPase Activities and Amino Acids Levels in Mice Hippocampus after Seizures. Chem. Biol. Interact.; 2015; 226, pp. 49-57. [DOI: https://dx.doi.org/10.1016/j.cbi.2014.12.001]

64. Kandhare, A.D.; Mukherjee, A.A.; Bodhankar, S.L. Anti-Epileptic Effect of Morin against Experimental Pentylenetetrazol-Induced Seizures via Modulating Brain Monoamines and Oxidative Stress. Asian Pac. J. Trop. Biomed.; 2018; 8, pp. 352-359. [DOI: https://dx.doi.org/10.4103/2221-1691.237078]

65. Zhang, L.; Wu, T.; Kandhare, A.; Mukherjee, A.; Guo, G.; Bodhankar, S. Elucidation of the Molecular Mechanism of Tempol in Pentylenetetrazol-Induced Epilepsy in Mice: Role of Gamma-Aminobutyric Acid, Tumor Necrosis Factor-Alpha, Interleukin-1β and c-Fos. Pharmacogn Mag.; 2018; 14, pp. S520-S527. [DOI: https://dx.doi.org/10.4103/pm.pm_263_18]

66. Tao, Z.; Chun-Yan, H.; Hua, P.; Bin-Bin, Y.; Xiaoping, T. Phyllathin From Phyllanthus Amarus Ameliorates Epileptic Convulsion and Kindling Associated Post-Ictal Depression in Mice via Inhibition of NF-ΚB/TLR-4 Pathway. Dose-Response; 2020; pp. 1-12. [DOI: https://dx.doi.org/10.1177/1559325820946914] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32821254]

67. Abd Allah, H.N.; Abdul-Hamid, M.; Mahmoud, A.M.; Abdel-Reheim, E.S. Melissa Officinalis L. Ameliorates Oxidative Stress and Inflammation and Upregulates Nrf2/HO-1 Signaling in the Hippocampus of Pilocarpine-Induced Rats. Environ. Sci. Pollut. Res.; 2022; 29, pp. 2214-2226. [DOI: https://dx.doi.org/10.1007/s11356-021-15825-y]

68. Wang, K.; Liu, Y.; Shi, Y.; Yan, M.; Rengarajan, T.; Feng, X. Amomum Tsaoko Fruit Extract Exerts Anticonvulsant Effects through Suppression of Oxidative Stress and Neuroinflammation in a Pentylenetetrazol Kindling Model of Epilepsy in Mice. Saudi J. Biol. Sci.; 2021; 28, pp. 4247-4254. [DOI: https://dx.doi.org/10.1016/j.sjbs.2021.06.007]

69. Vogt, A.G.; de Oliveira, R.L.; Voss, G.T.; Blödorn, G.B.; Alves, D.; Wilhelm, E.A.; Luchese, C. QCTA-1, a Quinoline Derivative, Ameliorates Pentylenetetrazole-Induced Kindling and Memory Comorbidity in Mice: Involvement of Antioxidant System of Brain. Pharmacol. Biochem. Behav.; 2022; 215, 173357. [DOI: https://dx.doi.org/10.1016/j.pbb.2022.173357] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/35196533]

70. Alkhudhayri, A.; Abdel Moneim, A.E.; Rizk, S.; Bauomy, A.A.; Dkhil, M.A. The Neuroprotective Effect Associated with Echinops Spinosus in an Acute Seizure Model Induced by Pentylenetetrazole. Neurochem. Res.; 2023; 48, pp. 273-283. [DOI: https://dx.doi.org/10.1007/s11064-022-03738-2]

71. Gad, R.A.; Abdel-Reheim, E.S.; Ebaid, H.; Alhazza, I.M.; Abuelsaad, A.S.A. Mitigating Effects of Passiflora incarnata on Oxidative Stress and Neuroinflammation in Case of Pilocarpine-Induced Status Epilepticus Model. J. King Saud Univ. Sci.; 2022; 34, 101886. [DOI: https://dx.doi.org/10.1016/j.jksus.2022.101886]

72. Garthwaite, J. Concepts of Neural Nitric Oxide-Mediated Transmission. Eur. J. Neurosci.; 2008; 27, pp. 2783-2802. [DOI: https://dx.doi.org/10.1111/j.1460-9568.2008.06285.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/18588525]

73. Girouard, H.; Wang, G.; Gallo, E.F.; Anrather, J.; Zhou, P.; Pickel, V.M.; Iadecola, C. NMDA Receptor Activation Increases Free Radical Production through Nitric Oxide and NOX2. J. Neurosci.; 2009; 29, pp. 2545-2552. [DOI: https://dx.doi.org/10.1523/JNEUROSCI.0133-09.2009] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/19244529]

74. Michaelis, E.K. Molecular Biology of Glutamate Receptors in the Central Nervous System and Their Role in Excitotoxicity, Oxidative Stress and Aging. Prog. Neurobiol.; 1998; 54, pp. 369-415. [DOI: https://dx.doi.org/10.1016/S0301-0082(97)00055-5]

75. Starkov, A.A.; Fiskum, G.; Chinopoulos, C.; Lorenzo, B.J.; Browne, S.E.; Patel, M.S.; Beal, M.F. Mitochondrial α-Ketoglutarate Dehydrogenase Complex Generates Reactive Oxygen Species. J. Neurosci.; 2004; 24, pp. 7779-7788. [DOI: https://dx.doi.org/10.1523/JNEUROSCI.1899-04.2004]

76. Kawamoto, E.M.; Cararo-Lopes, M.M.; Kinoshita, P.F.; Quintas, L.E.M.; Lima, L.S.; Andreotti, D.Z.; Scavone, C. Influence of Nitric Oxide–Cyclic GMP and Oxidative STRESS on Amyloid-β Peptide Induced Decrease of Na,K-ATPase Activity in Rat Hippocampal Slices. J. Membr. Biol.; 2021; 254, pp. 463-473. [DOI: https://dx.doi.org/10.1007/s00232-021-00196-9]

77. Petrillo, S.; Pietrafusa, N.; Trivisano, M.; Calabrese, C.; Saura, F.; Gallo, M.G.; Bertini, E.S.; Vigevano, F.; Specchio, N.; Piemonte, F. Imbalance of Systemic Redox Biomarkers in Children with Epilepsy: Role of Ferroptosis. Antioxidants; 2021; 10, 1267. [DOI: https://dx.doi.org/10.3390/antiox10081267]

78. Menon, B.; Ramalingam, K.; Kumar, R.V. Low Plasma Antioxidant Status in Patients with Epilepsy and the Role of Antiepileptic Drugs on Oxidative Stress. Ann. Indian Acad. Neurol.; 2014; 17, pp. 398-404. [DOI: https://dx.doi.org/10.4103/0972-2327.144008]

79. Hussein, S.A.; Abdel-Mageid, A.D.; Abd-Elhamed, O.M.; Al-Harthy, H.S. Biochemical Role of Curcumin on Kainic Acid-Induced Epilepsy in Male Swiss Albino Mice. Benha. Vet. Med. J.; 2014; 27, pp. 225-240.

80. Reddy, A.; Dubey, A.K.; Handu, S.; Sharma, P.; Mediratta, P.; Ahmed, Q.; Jain, S. Anticonvulsant and Antioxidant Effects of Musa Sapientum Stem Extract on Acute and Chronic Experimental Models of Epilepsy. Pharmacogn. Res.; 2018; 10, pp. 49-54. [DOI: https://dx.doi.org/10.4103/pr.pr_31_17]

81. Guo, X.; Wang, J.; Wang, N.; Mishra, A.; Li, H.; Liu, H.; Fan, Y.; Liu, N.; Wu, Z. Wogonin Preventive Impact on Hippocampal Neurodegeneration, Inflammation and Cognitive Defects in Temporal Lobe Epilepsy. Saudi J. Biol. Sci.; 2020; 27, pp. 2149-2156. [DOI: https://dx.doi.org/10.1016/j.sjbs.2020.05.030] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/32742183]

82. Ramazi, S.; Fahanik-Babaei, J.; Mohamadi-Zarch, S.M.; Tashakori-Miyanroudi, M.; Nourabadi, D.; Nazari-Serenjeh, M.; Roghani, M.; Baluchnejadmojarad, T. Neuroprotective and Anticonvulsant Effects of Sinomenine in Kainate Rat Model of Temporal Lobe Epilepsy: Involvement of Oxidative Stress, Inflammation and Pyroptosis. J. Chem. Neuroanat.; 2020; 108, 101800. [DOI: https://dx.doi.org/10.1016/j.jchemneu.2020.101800]

83. Moto, F.C.O.; Arsa’a, A.; Ngoupaye, G.T.; Taiwe, G.S.; Njapdounke, J.S.K.; Kandeda, A.K.; Nkantchoua, G.C.N.; Omam Omam, J.P.; Pale, S.; Kouemou, N.E. et al. Anxiolytic and Antiepileptic Properties of the Aqueous Extract of Cissus Quadrangularis (Vitaceae) in Mice Pilocarpine Model of Epilepsy. Front. Pharmacol.; 2018; 9, 751. [DOI: https://dx.doi.org/10.3389/fphar.2018.00751]

84. Aoyama, K.; Nakaki, T. Neuroprotective Properties of the Excitatory Amino Acid Carrier 1 (EAAC1). Amino Acids; 2013; 45, pp. 133-142. [DOI: https://dx.doi.org/10.1007/s00726-013-1481-5] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23462929]

85. Aoyama, K.; Sang, W.S.; Hamby, A.M.; Liu, J.; Wai, Y.C.; Chen, Y.; Swanson, R.A. Neuronal Glutathione Deficiency and Age-Dependent Neurodegeneration in the EAAC1 Deficient Mouse. Nat. Neurosci.; 2006; 9, pp. 119-126. [DOI: https://dx.doi.org/10.1038/nn1609]

86. Rodríguez-Campuzano, A.G.; Ortega, A. Glutamate Transporters: Critical Components of Glutamatergic Transmission. Neuropharmacology; 2021; 192, 108602. [DOI: https://dx.doi.org/10.1016/j.neuropharm.2021.108602]

87. Ueda, Y.; Doi, T.; Tokumaru, J.; Yokoyama, H.; Nakajima, A.; Mitsuyama, Y.; Ohya-Nishiguchi, H.; Kamada2, H.; Willmore, L.J. Collapse of Extracellular Glutamate Regulation during Epileptogenesis: Down-Regulation and Functional Failure of Glutamate Transporter Function in Rats with Chronic Seizures Induced by Kainic Acid. J. Neurochem.; 2001; 76, pp. 892-900. [DOI: https://dx.doi.org/10.1046/j.1471-4159.2001.00087.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11158261]

88. Ingram, E.M.; Wiseman, J.W.; Tessler, S.; Emson, P.C. Reduction of Glial Glutamate Transporters in the Parietal Cortex and Hippocampus of the EL Mouse. J. Neurochem.; 2001; 79, pp. 564-575. [DOI: https://dx.doi.org/10.1046/j.1471-4159.2001.00612.x] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/11701760]

89. Petr, G.T.; Sun, Y.; Frederick, N.M.; Zhou, Y.; Dhamne, S.C.; Hameed, M.Q.; Miranda, C.; Bedoya, E.A.; Fischer, K.D.; Armsen, W. et al. Conditional Deletion of the Glutamate Transporter GLT-1 Reveals That Astrocytic GLT-1 Protects against Fatal Epilepsy While Neuronal GLT-1 Contributes Significantly to Glutamate Uptake into Synaptosomes. J. Neurosci.; 2015; 35, pp. 5187-5201. [DOI: https://dx.doi.org/10.1523/JNEUROSCI.4255-14.2015]

90. Tanaka, K.; Watase, K.; Manabe, T.; Yamada, K.; Watanabe, M.; Takahashi, K.; Iwama, H.; Nishikawa, T.; Ichihara, N.; Kikuchi, T. et al. Epilepsy and Exacerbation of Brain Injury in Mice Lacking the Glutamate Transporter GLT-1. Science; 1997; 276, pp. 1699-1702. [DOI: https://dx.doi.org/10.1126/science.276.5319.1699] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/9180080]

91. Rothstein, J.D.; Dykes-Hoberg, M.; Pardo, C.A.; Bristol, L.A.; Jin, L.; Kuncl, R.W.; Kanai, Y.; Hediger, M.A.; Wang, Y.; Schielke, J.P. et al. Knockout of Glutamate Transporters Reveals a Major Role for Astroglial Transport in Excitotoxicity and Clearance of Glutamate. Neuron; 1996; 16, pp. 675-686. [DOI: https://dx.doi.org/10.1016/S0896-6273(00)80086-0]

92. Oja, S.S.; Janaky, R.; Varga, V.; Saransaari, P. Modulation of Glutamate Receptor Functions by Glutathione. Neurochem. Int.; 2000; 37, pp. 299-306. [DOI: https://dx.doi.org/10.1016/S0197-0186(00)00031-0]

93. Szaroma, W.; Dziubek, K.; Kapusta, E. Effect of N-Methyl-D-Aspartic Acid on Activity of Superoxide Dismutase, Catalase, Glutathione Peroxidase and Reduced Glutathione Level in Selected Organs of the Mouse. Acta Physiol. Hung.; 2014; 101, pp. 377-387. [DOI: https://dx.doi.org/10.1556/APhysiol.101.2014.003]

94. Lewandowski, Ł.; Kepinska, M.; Milnerowicz, H. Inhibition of Copper-Zinc Superoxide Dismutase Activity by Selected Environmental Xenobiotics. Environ. Toxicol. Pharmacol.; 2018; 58, pp. 105-113. [DOI: https://dx.doi.org/10.1016/j.etap.2017.12.022]

95. Taiwe, G.S.; Ndieudieu Kouamou, A.L.; Dabole, B.; Ambassa, A.R.M.; Mambou, H.M.A.Y.; Bila, R.B.; Tchoya, T.B.; Menanga, J.R.; Djomeni Dzeufiet, P.D.; Ngo Bum, E. Protective Effects of Anthocleista Djalonensis Extracts against Pentylenetetrazole-Induced Epileptic Seizures and Neuronal Cell Loss: Role of Antioxidant Defense System. Evid. Based Complement. Altern. Med.; 2021; 2021, 5523705. [DOI: https://dx.doi.org/10.1155/2021/5523705]

96. Tambe, R.; Jain, P.; Patil, S.; Ghumatkar, P.; Sathaye, S. Antiepileptogenic Effects of Borneol in Pentylenetetrazole-Induced Kindling in Mice. Naunyn-Schmiedeb. Arch. Pharmacol.; 2016; 389, pp. 467-475. [DOI: https://dx.doi.org/10.1007/s00210-016-1220-z]

97. Gao, F.; Gao, Y.; Liu, Y.F.; Wang, L.; Li, Y.J. Berberine Exerts an Anticonvulsant Effect and Ameliorates Memory Impairment and Oxidative Stress in a Pilocarpine-Induced Epilepsy Model in the Rat. Neuropsychiatr. Dis. Treat; 2014; 10, pp. 2139-2145. [DOI: https://dx.doi.org/10.2147/NDT.S73210] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25419137]

98. Ahmad, M.; Abu-Taweel, G.M.; Aboshaiqah, A.E.; Ajarem, J.S. The Effects of Quinacrine, Proglumide, and Pentoxifylline on Seizure Activity, Cognitive Deficit, and Oxidative Stress in Rat Lithium-Pilocarpine Model of Status Epilepticus. Oxid. Med. Cell. Longev.; 2014; 2014, 630509. [DOI: https://dx.doi.org/10.1155/2014/630509] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25478062]

99. Alvi, A.M.; Al Kury, L.T.; Alattar, A.; Ullah, I.; Muhammad, A.J.; Alshaman, R.; Shah, F.A.; Khan, A.U.; Feng, J.; Li, S. Carveol Attenuates Seizure Severity and Neuroinflammation in Pentylenetetrazole-Kindled Epileptic Rats by Regulating the Nrf2 Signaling Pathway. Oxid. Med. Cell. Longev.; 2021; 2021, 9966663. [DOI: https://dx.doi.org/10.1155/2021/9966663] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/34422216]

100. Liu, D.H.; Agbo, E.; Zhang, S.H.; Zhu, J.L. Anticonvulsant and Neuroprotective Effects of Paeonol in Epileptic Rats. Neurochem. Res.; 2019; 44, pp. 2556-2565. [DOI: https://dx.doi.org/10.1007/s11064-019-02874-6]

101. Kandeda, A.K.; Taiwe, G.S.; Moto, F.C.O.; Ngoupaye, G.T.; Nkantchoua, G.C.N.; Njapdounke, J.S.K.; Omam, J.P.O.; Pale, S.; Kouemou, N.; Bum, E.N. Antiepileptogenic and Neuroprotective Effects of Pergularia daemia on Pilocarpine Model of Epilepsy. Front. Pharmacol.; 2017; 8, 440. [DOI: https://dx.doi.org/10.3389/fphar.2017.00440]

102. Sani, M.; Sebaï, H.; Gadacha, W.; Boughattas, N.A.; Reinberg, A.; Mossadok, B.A. Catalase Activity and Rhythmic Patterns in Mouse Brain, Kidney and Liver. Comp. Biochem. Physiol. B Biochem.; 2006; 145, pp. 331-337. [DOI: https://dx.doi.org/10.1016/j.cbpb.2006.08.005]

103. Holm, T.H.; Lykke-Hartmann, K. Insights into the Pathology of the A3 Na⁺/K⁺-ATPase Ion Pump in Neurological Disorders; Lessons from Animal Models. Front. Physiol.; 2016; 7, 209. [DOI: https://dx.doi.org/10.3389/fphys.2016.00209]

104. Das, J.; Singh, R.; Sharma, D. Antiepileptic Effect of Fisetin in Iron-Induced Experimental Model of Traumatic Epilepsy in Rats in the Light of Electrophysiological, Biochemical, and Behavioral Observations. Nutr Neurosci.; 2017; 20, pp. 255-264. [DOI: https://dx.doi.org/10.1080/1028415X.2016.1183342] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/27198489]

105. Funck, V.R.; Ribeiro, L.R.; Pereira, L.M.; de Oliveira, C.V.; Grigoletto, J.; Fighera, M.R.; Royes, L.F.F.; Furian, A.F.; Oliveira, M.S. Long-Term Decrease in Na⁺,K⁺-ATPase Activity after Pilocarpine-Induced Status Epilepticus Is Associated with Nitration of Its Alpha Subunit. Epilepsy Res.; 2014; 108, pp. 1705-1710. [DOI: https://dx.doi.org/10.1016/j.eplepsyres.2014.09.025]

106. Marquezan, B.P.; Funck, V.R.; Oliveira, C.V.; Pereira, L.M.; Araújo, S.M.; Zarzecki, M.S.; Royes, L.F.F.; Furian, A.F.; Oliveira, M.S. Pentylenetetrazol-Induced Seizures Are Associated with Na⁺, K⁺-ATPase Activity Decrease and Alpha Subunit Phosphorylation State in the Mice Cerebral Cortex. Epilepsy Res.; 2013; 105, pp. 396-400. [DOI: https://dx.doi.org/10.1016/j.eplepsyres.2013.03.007]

107. Bogdanova, A.; Petrushanko, I.Y.; Hernansanz-Agustín, P.; Martínez-Ruiz, A. “Oxygen Sensing” by Na,K-ATPase: These Miraculous Thiols. Front. Physiol.; 2016; 7, 314. [DOI: https://dx.doi.org/10.3389/fphys.2016.00314]

108. Petrushanko, I.Y.; Mitkevich, V.A.; Lakunina, V.A.; Anashkina, A.A.; Spirin, P.V.; Rubtsov, P.M.; Prassolov, V.S.; Bogdanov, N.B.; Hänggi, P.; Fuller, W. et al. Cysteine Residues 244 and 458–459 within the Catalytic Subunit of Na,K-ATPase Control the Enzyme’s Hydrolytic and Signaling Function under Hypoxic Conditions. Redox Biol.; 2017; 13, pp. 310-319. [DOI: https://dx.doi.org/10.1016/j.redox.2017.05.021] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/28601781]

109. Poluektov, Y.M.; Dergousova, E.A.; Lopina, O.D.; Mitkevich, V.A.; Makarov, A.A.; Petrushanko, I.Y. Na,K-ATPase α-Subunit Conformation Determines Glutathionylation Efficiency. Biochem. Biophys. Res. Commun.; 2019; 510, pp. 86-90. [DOI: https://dx.doi.org/10.1016/j.bbrc.2019.01.052]

110. Petrushanko, I.Y.; Yakushev, S.; Mitkevich, V.A.; Kamanina, Y.V.; Ziganshin, R.H.; Meng, X.; Anashkina, A.A.; Makhro, A.; Lopina, O.D.; Gassmann, M. et al. S-Glutathionylation of the Na, K-ATPase Catalytic α Subunit Is a Determinant of the Enzyme Redox Sensitivity. J. Biol. Chem.; 2012; 287, pp. 32195-32205. [DOI: https://dx.doi.org/10.1074/jbc.M112.391094]

111. Genda, E.N.; Jackson, J.G.; Sheldon, A.L.; Locke, S.F.; Greco, T.M.; O’Donnell, J.C.; Spruce, L.A.; Xiao, R.; Guo, W.; Putt, M. et al. Co-Compartmentalization of the Astroglial Glutamate Transporter, GLT-1, with Glycolytic Enzymes and Mitochondria. J. Neurosci.; 2011; 31, pp. 18275-18288. [DOI: https://dx.doi.org/10.1523/JNEUROSCI.3305-11.2011]

112. Rose, E.M.; Koo, J.C.P.; Antflick, J.E.; Ahmed, S.M.; Angers, S.; Hampson, D.R. Glutamate Transporter Coupling to Na,K-ATPase. J. Neurosci.; 2009; 29, pp. 8143-8155. [DOI: https://dx.doi.org/10.1523/JNEUROSCI.1081-09.2009]

113. Bélanger, M.; Allaman, I.; Magistretti, P.J. Brain Energy Metabolism: Focus on Astrocyte-Neuron Metabolic Cooperation. Cell Metab.; 2011; 14, pp. 724-738. [DOI: https://dx.doi.org/10.1016/j.cmet.2011.08.016] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/22152301]

114. Illarionava, N.B.; Brismar, H.; Aperia, A.; Gunnarson, E. Role of Na,K-ATPase A1 and A2 Isoforms in the Support of Astrocyte Glutamate Uptake. PLoS ONE; 2014; 9, e110095. [DOI: https://dx.doi.org/10.1371/journal.pone.0098469] [PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24901986]

115. Sumbul, O.; Aygun, H. Chronic Effects of Different Quercetin Doses in Penicillin-Induced Focal Seizure Model. Neurosci. Lett.; 2021; 753, 135848. [DOI: https://dx.doi.org/10.1016/j.neulet.2021.135848]

116. Shawki, M.; El Wakeel, L.M.; Shatla, R.; El-Saeed, G.; Ibrahim, S.; Badary, O. The Clinical Outcome of Adjuvant Therapy with Black Seed Oil on Intractable Paediatric Seizures: A Pilot Study. Epileptic Disord.; 2013; 15, pp. 295-301. [DOI: https://dx.doi.org/10.1684/epd.2013.0602]

117. Colomeu, T.C.; de Figueiredo, D.; de Zollner, R.L.; Meletti, L.M.M. Comparison of Antioxidant and Ant Proliferative Effect among Four Passiflora Spp. J. Agric. Life Sci.; 2017; 4, pp. 2375-4222.

118. Appel, K.; Rose, T.; Fiebich, B.; Kammler, T.; Hoffmann, C.; Weiss, G. Modulation of the γ-Aminobutyric Acid (GABA) System by Passiflora incarnata L. Phytother Res.; 2011; 25, pp. 838-843. [DOI: https://dx.doi.org/10.1002/ptr.3352]